Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ATX-101 for reduction of submental subcutaneous fat
2007-006303-21Phase 2Completed
- Sponsor
- Kythera Biopharmaceuticals
- Start
- Dec 2007
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ATX101 in Submental lipomatosis (4 arms), sponsored by Kythera Biopharmaceuticals. Primary endpoints: Safety and tolerability of ATX-101 and Efficacy in reducing submental subcutaneous fat. Started Dec 2007; status: completed.
02
Drugs
ATX101
03
Conditions
Submental lipomatosis
Beyond the preview
Go deeper on 2007-006303-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006303-21.